by z-john
When AI Meets Immunology: How Scientists Can Use Machine Learning to Win the Next Viral War
| April 2026 Latest Research Abstract | Frontiers in B Cells and Antibodies |
Your Body Has an Army
Every time you recover from a cold, it’s not by chance. Your immune system has a group of soldiers called B cells, whose job is to produce antibodies—protein weapons specifically designed to identify and destroy viruses.
The problem is, viruses mutate.
From the original strain to Delta and Omicron, each mutation of the novel coronavirus has reduced the effectiveness of previous antibodies. This is like your army only recognizing an old photograph of the enemy, but when the enemy changes disguises, the soldiers can’t recognize them.
Scientists are now asking: Is there a way to make vaccines provide broader and longer-lasting protection?
The latest answer comes from artificial intelligence.
How AI Helps Scientists Choose Weapons
A recent study published on bioRxiv used AI to analyze 97 fragments of proteins from 19 different viruses, searching for “conserved regions” that have remained almost unchanged across different coronaviruses.
Why look for these conserved regions?
Because if certain parts of a virus mutate, it will die—these parts are the virus’s “vital points,” and they are unlikely to change easily. If a vaccine can make the immune system target these vital points, then no matter how the virus mutates, it will be difficult to escape recognition.
What AI is doing here is equivalent to helping scientists quickly find those few doors that will never move in a maze with tens of thousands of doors.
The results are very encouraging: the more conserved the fragment, the stronger the T-cell immune response. Furthermore, these fragments can be used to create mRNA vaccines, successfully inducing an immune response in mice.
While this research focuses on T cells, it represents a new direction—using AI to guide vaccine design, moving beyond manual trial and error.
More Antibodies Aren’t Always Better: A Key Discovery
Another study revealed a surprising finding directly related to the quality of antibodies produced by B cells.
Scientists tracked hospitalized patients during the first wave of the COVID-19 pandemic, comparing early immune responses in mild and severe cases. They used proteomics and systematic serology—technologies capable of simultaneously analyzing the function of thousands of antibodies.
The findings are very clear: In patients with mild symptoms, B cells quickly produce antibodies targeting the S1 region of the virus (the first half of the spike protein). These antibodies have a unique ability—they activate phagocytes, allowing the immune system to engulf the virus like Pac-Man. This ability is called the Fc effector function.
In severely ill patients, the opposite is true: their B cells produce antibodies biased towards the S2 region (the second half of the spike protein), and these antibodies have poor Fc effector function—numerous in number, but weak in effectiveness.
To use an analogy: the antibodies in patients with mild symptoms are like a special forces unit, precisely targeting the enemy; the antibodies in severely ill patients are like a ceremonial guard, appearing orderly but ineffective in combat.
This discovery tells us that future vaccine design must not only enable B cells to produce more antibodies, but also ensure the quality and function of those antibodies.
The Mysterious Antibodies of Long-Term COVID-19 Patients: The Answer is Surprising
Some COVID-19 survivors suffer from prolonged neurological symptoms such as “brain fog” and memory loss; this condition is known as neurogenic long-term COVID-19.
The scientific community has long suspected that this might be due to the immune system “misbehaving,” producing autoantibodies that attack the brain itself—in other words, B cells producing antibodies that target the wrong target.
A recent multi-cohort study analyzed the cerebrospinal fluid and serum of long-term COVID-19 patients using a technique called PhIP-Seq, which can simultaneously screen for tens of thousands of possible autoantibodies.
The results were unexpected: long-term COVID-19 patients did not share a common autoantibody characteristic.
Each patient’s autoantibodies were different, and a single, unified “culprit” could not be found. This suggests that neurogenic COVID-19 is likely not caused by a single autoimmune mechanism, but rather by multiple different causes—in some cases, inflammation; in others, nerve damage; and in still others, other problems.
While this finding doesn’t provide an answer, it eliminates one avenue, allowing scientists to focus their attention on other mechanisms. Knowing “what it isn’t” is equally important in scientific research.
Next-Generation Vaccines: An Upgrade to mRNA Technology
Beyond this basic research, there is a more realistic development—the benefit assessment of the next-generation COVID-19 vaccine, mRNA-1283.
Dutch researchers have built a mathematical model to calculate the benefits of replacing existing vaccines with this new one.
The conclusion is that without any vaccination, the Netherlands is projected to see 460,000 infections, 23,800 hospitalizations, and 5,300 deaths within a year. mRNA-1283 can reduce hospitalizations by approximately 1300 times compared to existing methods.
More importantly, this vaccine offers longer-lasting protection for the elderly and high-risk groups compared to older versions.
The principle behind mRNA technology is that your cells temporarily read a segment of the genome, creating a part of the virus themselves. B cells then learn to produce the corresponding antibodies—the entire process does not require the actual virus.
A Common Theme
Looking at these studies together, a common signal emerges:
Immunology is moving from “extensive” to “precision.”
In the past, we only knew that more antibodies were better. Now we know that antibodies must target the right sites (S1 instead of S2), have the correct function (Fc effect), and target conserved regions that are less prone to mutation.
AI is playing an increasingly important role in this precision process—not to replace scientists, but to help them find the right direction more quickly among billions of possibilities.
Humanity will be better prepared for the next pandemic.
tags: AI, - Immunology,